Shalu Pahuja

  • Citations Per Year
Learn More
Clinically detectable regional lymph node melanoma metastasis (AJCC stage IIIB-C) carries a risk of relapse and death that approaches 70% at 5 years. Surgical management is the cornerstone of therapy, with postoperative adjuvant therapy utilizing high-dose interferon alfa-2b (HDI). Neoadjuvant chemotherapy or immunotherapy in addition to surgery has been(More)
7093 Background: Tumor necrosis factor-alpha (TNF-alpha) enhances tumor growth and mediates cancer-related inflammatory symptoms by inducing secretion of cytokines. Anti-TNF approaches have been evaluated in pilot studies for cancer treatment and for alleviation of cancer related cachexia, fatigue, and other constitutional symptoms with conflicting results.(More)
8583 Antibody dependent cellular citotoxicity (ADCC) play a significant role in rituximab's anti-tumor activity. FcγRIIIa polymorphisms have been associated with clinical responses to rituximab. The predictive value of FcγRIIIa polymorphisms is lost when rituximab is combined with chemotherapy. Alternative assays to assess the immune system had not been(More)
Breast cancer brain metastases (BCBMs) are challenging, as they can occur up to several years after diagnosis and in the setting of controlled extracranial disease. Increased survival of breast cancer patients through more effective systemic treatments has unmasked a subpopulation with central nervous system (CNS) metastases, which is now one of the major(More)
  • 1